Your browser doesn't support javascript.
loading
Timing of elimination of hepatitis C virus in Canada's provinces.
Feld, Jordan J; Klein, Marina B; Rahal, Yasmine; Lee, Samuel S; Mohammed, Shawn; King, Alexandra; Smyth, Daniel; Gonzalez, Yuri Sanchez; Nugent, Arlene; Janjua, Naveed Z.
Afiliação
  • Feld JJ; Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Klein MB; Department of Medicine, McGill University Health Centre, Montreal, Québec, Canada.
  • Rahal Y; AbbVie Corporation, Saint-Laurent, Québec, Canada.
  • Lee SS; Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Mohammed S; AbbVie Corporation, Saint-Laurent, Québec, Canada.
  • King A; College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Smyth D; Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Gonzalez YS; AbbVie, Inc., North Chicago, Illinois, United States.
  • Nugent A; AbbVie, Inc., North Chicago, Illinois, United States.
  • Janjua NZ; BC Centre for Disease Control, Vancouver, British Columbia, Canada.
Can Liver J ; 5(4): 493-506, 2022 Nov.
Article em En | MEDLINE | ID: mdl-38144411
ABSTRACT

BACKGROUND:

Infection with chronic hepatitis C virus is a global public health concern. A recent study concluded that Canada is on track to achieve hepatitis C elimination goals set by the World Health Organization if treatment levels are maintained. However, recently a falling temporal trend in treatments in Canada was observed, with most provinces seeing a decrease before the global coronavirus pandemic. This study assesses the timing of elimination of hepatitis C in the 10 provinces of Canada.

METHODS:

Previously published disease and economic burden model of hepatitis C infection was populated with the latest epidemiological and cost data for each Canadian province. Five scenarios were modelled maintaining the status quo, decreasing diagnosis and treatment levels by 10% annually, decreasing diagnosis and treatment levels by 20% annually, increasing them by 10% annually, and assuming a scenario with no post-coronavirus pandemic recovery in treatment levels. Year of achieving hepatitis C elimination, necessary annual treatments for elimination, and associated disease and economic burden were determined for each province.

RESULTS:

If status quo is maintained, Manitoba, Ontario, and Québec are off track to achieve hepatitis C elimination by 2030 and would require 540, 7,700, and 2,800 annual treatments, respectively, to get on track. Timely elimination would save 170 lives and CAD $122.6 million in direct medical costs in these three provinces.

CONCLUSIONS:

Three of Canada's provinces-two of them the most populous in the country-are off track to achieve the hepatitis C elimination goal. Building frameworks and innovative approaches to prevention, testing, and treatment will be necessary to achieve this goal.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Can Liver J Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá País de publicação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Can Liver J Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá País de publicação: Canadá